Singapore, Mar 19, 2010: Melbourne based HealthLinx is looking at launching its OvPlex, Ovarian Cancer Diagnostic Test in Singapore in the second quarter of 2010. The company is also in discussions with companies in other Asian countries. The discussions are at an advanced stage for distribution in South Korea. Significant progress has also been made towards the planned distribution in China.

Mr Nick Gatsios, managing director, HealthLinx said, “As we predicted, 2010 is shaping up to be the year OvPlex becomes available to millions of women across the globe. The company is continuing to meet or exceed its milestones. This has placed HealthLinx in an excellent position going into the second quarter of 2010.”

HealthLinx has assembled some of the leading ovarian cancer experts from Singapore, UK and Australia to evaluate the effectiveness of OvPlex in this second stage trial. The official commencement of the second study to improve the sensitivity and specificity of OvPlex to an anticipated and unprecedented greater than 97% is imminent with all necessary agreements signed, ethics granted and the first 425 samples secured.

HealthLinx has sponsored Simon Curtis in his ovarian cancer awareness and fundraising bike ride around mainland Britain. Simon set off on his bike ride on March 14 with a goal to make more people aware of ovarian cancer and its symptoms.